hsp70

Vaccineexperimental

The 70 kilodalton heat shock proteins are a family of conserved ubiquitously expressed heat shock proteins. Proteins with similar structure exist in virtually all living organisms and play crucial roles in the development of cancer, neurodegeneration, apoptosis, regulating sleep, and much more. Intracellularly localized Hsp70s are an important part of the cell's machinery for protein folding, performing chaperoning functions, and helping to protect cells from the adverse effects of physiological stresses. Additionally, membrane-bound Hsp70s have been identified as a potential target for cancer therapies and their extracellularly localized counterparts have been identified as having both membrane-bound and membrane-free structures. There is lot of potential in the Hsp70 protein as a key therapeutic target for developing new drugs for the treatment of sleep disorders, cancer, neurodegeneration, and other related pathological conditions. — Wikipedia

Clinical trial activity

2 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2000 (NCT00027144)

Timeline

2000s

  1. Jan 1, 2000

    Earliest Phase 1 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • hsp70
  • hsp70

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00027131Phase 1/Phase 2 (Phase 2)Dec 1, 2000University of Connecticut
NCT00027144Phase 1Dec 1, 2000University of Connecticut
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of ConnecticutAcademic/Hospital2222000
1 organizations
Page 1 / 1